Dyslipidemia in chronic kidney disease excluding diabetic and nephrotic aetiology

Rajendran Velayudham, Senthilkumar Sivasubramanian


Background: Dyslipidemia is hypothesized as one of the risk factor of chronic kidney disease and plays an important role in the progression of renal failure. The present study was conducted to assess the association between ratio of TG/HDL-C and CKD and other abnormalities in the lipid profile in CKD patients.

Methods: This case-control study was conducted in Government General Hospital from July 2013 to November 2013. 100 patients with CKD were included as study cases. 100 healthy patients from the same hospital, who came with different illness other than the study disease were included as controls. Fasting lipid profile was done – total cholesterol, triglycerides and high-density lipoproteins (HDL) were measured and low-density lipoproteins, & TG/HDL ratio were calculated. Comparison of lipid parameters among study and control groups was done. P value <0.05 was considered as statistically significant.

Results: Majority of the study patients were under the age group of 40-50 years. Male dominance (86%) was seen in the study group. The association of HDL, LDL, TGL, TGL/HDL, TC parameters and stages of CKD was observed and found to be statistically significant (p value <0.0001 and <0.05). Comparison of lipid parameters among study and control groups were done and difference was found to be statistically significant (p value <0.0001).

Conclusions: Dyslipidemia should be treated in early stages of CKD to prevent secondary complications.


Cardiovascular disease, Chronic Kidney disease, Lipid abnormalities

Full Text:



Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Inter. 2013;3:1-150.

World Health Organisation. Burden of disease project. Available at: Accessed on September 2006.

Bamgboye EL. Hemodialysis: management problems in developing countries, with Nigeria as a surrogate. Kidney Int. 2003;63(83).

Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-53.

Brenner BM. Brenner and Rector's The Kidney. In: Ramesh Saxena & Robert D. Toto, editors. Approach to the Patient with Kidney Disease. Boston, MA: Saunders; 2007(20 pp, 200 refs).

Attman PO, Alaupovic P, Samuelsson O. Lipoprotein abnormalities as a risk factor for progressive non-diabetic renal disease. Kidney Int. 1999;56:14-7.

Toto RD, Vega G, Grundy SM. Cholesterol management in patients with chronic kidney disease. In: Brayd H, Wilcox C, editors. Therapy in Nephrology and Hypertension. Philadelphia and New York: Lippincott - Williams & Wilkins; 2003: 631-9.

Kronenberg F, Kuen E, Ritz E, Junker R, König P, Kraatz G, et al. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol. 2000;11:105-15.

Garg G, Chawla SMS, Kaur S. A Clinical Study Of Dyslipidemia In Patients Of Chronic Kidney Disease. Intl J Bioassays. 2015;4(3):3732-7.

Bhargavi MV. A Case-Control Study Of Prevalence And Type Of Dyslipidemia In Chronic Kidney Disease. Int J Pharm Bio Sci. 2015;6(2):93-102.

Ljutfi Z, Koco C, Todor G, Lipid profile and concentration of ApoA-1 and ApoB-100 in patients with end-stage renal disease treated by repeated hemodialysis, Sec Biol Med Sci. 2008;29;141-52.

Shah B, Nair S, Sirsat RA, Ashavaid TF, Nair K. Dyslipidemia in patients with chronic renal failure and in transplant patients. J Postgraduate Med. 1994;40:57-60.

Gupta DK. Hyperdipidemia in patents of chronic renal failure. Bombay Hospital J. 1991;33:45-50.